These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8993442)

  • 1. Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1.
    Lutz EM; MacKenzie CJ; Morrow J; Mitchell R; Bennie J; Carroll S; Clark E; Harmar AJ
    Ann N Y Acad Sci; 1996 Dec; 805():574-8. PubMed ID: 8993442
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular characterisation of novel receptors for PACAP and VIP.
    Lutz EM; Mendelson S; West K; Mitchell R; Harmar AJ
    Biochem Soc Trans; 1995 Feb; 23(1):83S. PubMed ID: 7758803
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
    Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
    Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism.
    MacKenzie CJ; Lutz EM; McCulloch DA; Mitchell R; Harmar AJ
    Ann N Y Acad Sci; 1996 Dec; 805():579-84. PubMed ID: 8993443
    [No Abstract]   [Full Text] [Related]  

  • 8. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion.
    Inagaki N; Kuromi H; Seino S
    Ann N Y Acad Sci; 1996 Dec; 805():44-51; discussion 52-3. PubMed ID: 8993392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X; Wang HY; Yu J; Ganea D
    Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct receptors mediate pituitary adenylate cyclase-activating peptide- and vasoactive intestinal peptide-induced relaxation of rat ileal longitudinal muscle.
    Ekblad E; Sundler F
    Eur J Pharmacol; 1997 Sep; 334(1):61-6. PubMed ID: 9346329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
    J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
    Juarranz MG; Bolaños O; Gutiérrez-Cañas I; Lerner EA; Robberecht P; Carmena MJ; Prieto JC; Rodríguez-Henche N
    Cell Signal; 2001 Dec; 13(12):887-94. PubMed ID: 11728828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor.
    Delporte C; Poloczek P; de Neef P; Vertongen P; Ciccarelli E; Svoboda M; Herchuelz A; Winand J; Robberecht P
    Mol Cell Endocrinol; 1995 Jan; 107(1):71-6. PubMed ID: 7796937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP, and carbachol: role in prostatic proliferation.
    Guijarro LG; Juarranz MG; Marinero MJ; Pajuelo L; Carmena MJ; Prieto JC
    Ann N Y Acad Sci; 1996 Dec; 805():723-8. PubMed ID: 8993468
    [No Abstract]   [Full Text] [Related]  

  • 16. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
    Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
    Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
    Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rat aortic smooth-muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor.
    Miyata A; Sato K; Hino J; Tamakawa H; Matsuo H; Kangawa K
    Ann N Y Acad Sci; 1998 Dec; 865():73-81. PubMed ID: 9927999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenylate cyclase-activating polypeptide triggers dual transduction signaling in CATH.a cells and transcriptionally activates tyrosine hydroxylase and c-fos expression.
    Muller A; Monnier D; Rene F; Larmet Y; Koch B; Loeffler JP
    J Neurochem; 1997 Apr; 68(4):1696-704. PubMed ID: 9084443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.